Name:
Tivey2022_Article_CirculatingT ...
Size:
869.7Kb
Format:
PDF
Description:
Identified with Open Access button
Affiliation
The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. Division of Cancer Sciences, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK. Nucleic Acids Biomarker Team, Cancer Research UK Manchester Institute, Cancer Biomarker Centre, The University of Manchester, Alderley Park, SK10 4TG, UK. The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. Rebecca.lee-3@manchester.ac.uk. Division of Cancer Sciences, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK. Rebecca.lee-3@manchester.ac.uk. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. Rebecca.lee-3@manchester.ac.uk.Issue Date
2022
Metadata
Show full item recordAbstract
Purpose of Review Liquid biopsies, including circulating tumour DNA (ctDNA), can inform a variety of clinical questions. This review examines the potential role of ctDNA as a clinical tool to inform clinical decision-making from early to late stage cutaneous melanoma. Recent Findings In pre-clinical studies, ctDNA has been shown to detect minimal residual disease and molecular relapse; predict and monitor response to therapy; and identify key resistance mechanisms. Here, we examine the potential utility of ctDNA and discuss its limitations for use in patients with melanoma. We present novel clinical trials, which are testing its value as a tool to augment clinical decision-making. Finally, we discuss the steps that are needed to ensure that ctDNA is used optimally in order to improve outcomes for patients with melanoma. Summary Preclinical studies have shown that ctDNA has huge potential to provide real-time information about disease status in patients with melanoma. It is now time to test it rigorously within clinical trials to assess how it can be optimally used to benefit patients in the clinic.Citation
Tivey A, Britton F, Scott J-A, Rothwell D, Lorigan P, Lee R. Circulating Tumour DNA in Melanoma—Clinic Ready? [Internet]. Vol. 24, Current Oncology Reports. Springer Science and Business Media LLC; 2022. p. 363–73.Journal
Curr Oncol RepDOI
10.1007/s11912-021-01151-6PubMed ID
35133615Additional Links
https://dx.doi.org/10.1007/s11912-021-01151-6Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s11912-021-01151-6